Alphamab Oncology will convene its 2026 annual general meeting (AGM) on 12 June 2026 at the company’s Suzhou headquarters. Key proposals up for shareholder approval include fresh share buy-back and issuance mandates, board re-elections, and the re-appointment of Deloitte Touche Tohmatsu as external auditor.

Share capital actions • Share repurchase mandate: Directors request authority to buy back up to 10% of issued share capital (excluding treasury shares) as at the AGM date—equivalent to 96.86 million shares based on the latest issued total of 968.57 million shares. • Issuance mandate: Management seeks approval to allot, issue or transfer up to 20% of the issued share capital—approximately 193.71 million shares—with an additional extension equal to the number of shares repurchased under the buy-back mandate. • Existing treasury stock: Over the six months to 15 May 2026, the company repurchased 1.65 million shares on the Hong Kong Stock Exchange at HK$9.24–10.48, all held as treasury shares.

Board composition Four directors are subject to retirement by rotation and stand for re-election: 1) Executive Director and Chief Operating Officer Liu Yang. 2) Independent Non-executive Director Wu Dong. 3) Independent Non-executive Director Wong Yan Ki Angel. 4) Independent Non-executive Director Gao Xiang. The Nomination Committee and the Board support all four re-appointments, citing their experience and contributions.

Auditor re-appointment The Audit Committee recommends re-appointing Deloitte Touche Tohmatsu. The estimated audit fee for FY2026 is RMB1.80 – 1.90 million, subject to final scope and timing.

Key timetable • Last day to lodge share transfers: 8 June 2026 (4:30 p.m.) • Books closure: 9 – 12 June 2026 (both days inclusive) • Record date for AGM voting: 12 June 2026 • Proxy submission deadline: 10:00 a.m., 10 June 2026

Voting at the AGM will be conducted by poll. The Board recommends shareholders vote in favour of all proposed resolutions.